報價延遲最少15分鐘:2025/11/19 11:06 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.64 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.23/-5.17
|
|
企業價值
11.18M
|
| 資產負債 |
|
每股賬面淨值
8.06
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/19 11:06 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorderswith high unmet medical need. |
